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Introduction
Oesophageal mediastinal fistula or oesophago-airway fistula 
(OAF) is a life-threatening complication of unresectable 
oesophageal or lung cancer, and requires prompt palliative 
treatment. In this setting, stenting is a procedure of choice. 
The incidence of oesophago-airway fistula in the course 
of inoperable oesophageal carcinoma increased over the 
last 30 years to above 10%, due to wider uses of advanced 
treatment such as chemotherapy, chemo-radiotherapy or 
stenting procedures (1). This type of palliative treatment 
aims at improving patients’ comfort, preventing septic 
complications in the form of severe respiratory and 
mediastinal infections and usually enables oral nutrition. In 
the published literature, there is only one paper comparing 
unilateral stenting (oesophageal or airway only) with double 
stenting (both: the oesophagus and the airway). In this 
study, we analyse our experience with both these methods. 
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vs. double stenting (DS) are scarce.
Methods: Retrospective analysis of hospital records of patients with oesophageal fistula who underwent 
stenting between 2008 and 2016. In those in whom airway stenosis was >30%, double stenting (oesophagus 
and bronchial tree) was performed, whereas in those with lesser airway stenosis unilateral stenting (i.e., 
oesophagus only) was performed. In all patients, the degree of dysphagia, the degree of dyspnoea and the 
quality of life were assessed before and after the stenting.
Results: There were 46 patients, analysed, including 26 who underwent DS and 20 patients who underwent 
US. Both, DS and US resulted in significant improvement of dysphagia (2.72 vs. 1.2, P=0.0001 and 2.65 vs. 
1.0, P=0.0001), dyspnoea (2.89 vs. 0.34, P=0.0001 and 1.71 vs. 0.09, P=0.0001) and performance score (53.2 
vs. 66.3, P=0.0001 and 54.3 vs. 62.38, P=0.0001). Neither fistula type, nor stenting method, weight loss and 
gain, and BMI, had an effect on survival (P=0.34). Disease progression and recurrence of fistula requiring re-
intervention occurred in 9 patients (19.5%). 
Conclusions: Double and unilateral stenting is an effective measure to alleviate dysphagia and dyspnoea 
in patients treated with malignant oesophageal fistula. In those with airway stenosis of ≤30%, stenting of the 
oesophagus only, instead of DS, is a safe method of treatment.
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Methods
Clinical characteristics
This retrospective study included data for a consecutive 
group of patients with OAF treated in one institution 
between 2008 and 2016. Due to the character of the study, 
i.e. retrospective analysis of hospital records, the approval 
of the Ethical Committee was waived. Patients received 
simultaneous double stenting of the oesophagus and airway 
or only unilateral stenting of the oesophagus. Patients with 
the Karnofsky score <40, and patients with the oesophageal 
mediastinal fistula were excluded from the study group (2). 
Also, patients with involvement of the oesophagus <3 cm from 
the upper esophageal sphincter and those without stenosis 
of the bronchial tree were excluded from the study. The 
characteristics of the group studied are presented in Table 1.
The patients were divided into two groups, according to 
the treatment received: 
 Double stenting (DS) group—patients who 
underwent stenting of the oesophagus and the airway;
 Unilateral stenting (US) group—patients who 
underwent stenting of the oesophagus only.
The preoperative work-up included a chest radiogram, 
computer i zed  tomography,  e sophagoscopy,  and 
bronchoscopy. Cancer stage was assessed according to the 
7th revision of the TNM classification (3).
Mean degree of dysphagia and mean degree of dyspnoea 
before and after the stenting procedure were assessed 
according to a four-grade scale (4): 
 0—no dysphagia;
 1—able to swallow semi-liquid food;
 2—able to swallow liquids;
 3—unable to swallow liquids and saliva.
Degree of stenosis of bronchial lumen and the degree 
of dyspnoea were assessed according to the original, four-
grade scale (5):
 Stenosis of the bronchial lumen <30%, no 
dyspnoea; 
 Stenosis of the bronchial lumen 30–50%, dyspnoea 
on exercise; 
 Stenosis of the bronchial lumen 50–70%, dyspnoea 
on short-distance walk;
 Stenosis of the bronchial lumen >70%, dyspnoea 
on rest.
Patients with oesophageal fistula were classified 
according to the original classification depending on the 
fistula location (5): 
 Type I—oesophageal-mediastinal fistula, without 
penetration to the bronchial tree;
 Type II—oesophageal fistula penetrating to the 
trachea;
 Type III—oesophageal fistula penetrating to the 
carina and/or main bronchus/bronchi.
Criteria for stenting procedure were as follows:
(I) Double stenting:
 Patients with unresectable oesophageal carcinoma 
with the fistula penetrating to the airway with 
bronchial tree stenosis >30%, assessed using CT 
and bronchoscopy;
(II) Unilateral (oesophageal) stenting:
 Patients with fistula penetrating to the airway, with 
airway stenosis ≤30%; 
 Lack of patient’s consent for double stenting.
Patients with type I fistula were excluded from the study 
group.
Intervention
The airway patency was restored mechanically, under 
general anaesthesia, with the use of rigid bronchoscopes 
of 6.5, 7.5 and 8.5 mm diameters (Karl Storz, Tuttlingen, 
Germany), with argon plasma coagulation (APC, Covidien, 
Minneapolis, USA) or laser treatment (MY 40 1.3, KLS 
Martin GmbH & Co. KG, Freiburg, Germany). Silicone 
Y stents (Demed, Mikołów, Poland) and covered SEMS 
(Ultraflex Boston Scientific Natick, MA, USA) were used 
(Figure 1A). The Y-type stents were implanted with the 
use of Freitag forceps according to the method described 
earlier, whereas the self-expandable bronchial stents were 
placed after bronchial dilatation under bronchoscopic 
control (6,7).
Oesophageal stenting was performed under general 
anaesthesia. The location of stenosis and the distance 
from the upper oesophageal sphincter were endoscopically 
identified and then the dilatation was performed with the 
use of Savary-Gilliard dilators (Cook Medical, Bloomington, 
USA), up to the size of 8–10 Fr. After the dilatation, the 
length of involved oesophageal segment was assessed using a 
standard Olympus series 180 endoscope (Olympus Medical 
Systems Corporation, Tokyo, Japan), then a guidewire was 
inserted and the oesophageal stent was introduced over it. 
The size of the stent was selected to cover the fistula and 
a 3–4 cm margin of oesophageal wall above and below it. 
Partially covered Ultraflex SEMS (Boston Scientific, Natick, 
USA) were used (Figure 1B and Figure 2).
Percutaneous endoscopic gastrostomy (PEG) was 
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performed according to the technique described elsewhere, 
after restoration of patency of the oesophagus (8).
Following the stenting procedure, chest X-ray was 
performed. On the first day after stenting the dyspnoea 
and dysphagia were assessed. Semi-liquid diet was allowed 
and patients received detailed information regarding the 
regimen of oral nutrition whilst stented. 
In the postoperative period, patients underwent a 
medical check-up on the first day after the procedure and 
then every 30 days. If necessary, additional follow-up visits 
were planned after phone confirmation. The follow-up 
included chest X-ray, esophagoscopy, bronchoscopy and, if 
necessary, computed tomography. During a follow-up visit 
patient’s overall condition, performance status, dyspnoea 
and dysphagia were assessed. 
Statistical analysis
Statistical analysis was performed using the STATISTICA 
10 PL software package (StatSoft, Tulsa Oklahoma, USA). 
Differences between two groups were tested with Gehan-
Wilcoxon’s, Kruskal-Wallis and Mann-Whitney tests. 
Log-rank, Chi-square, Fisher’s tests and odds ratio were 
calculated to compare groups for complications and re-
interventions. Survival time was calculated using Kaplan-
Meier method. P<0.05 was considered as statistically 
significant. 
Results
Between 2008 and 2016, 46 patients with oesophageal 
fistula underwent stenting. In 26 of them, in whom airway 
stenosis exceeded 30%, DS was performed, whereas in 20 
patients with lesser airway stenosis US was performed.
Results of stenting
The DS group included 26 patients with squamous 
cell oesophageal cancer. In all but one of them the 
procedure was performed electively. Mean body weight 
loss was 10.6 kg (range, 0–30 kg). In the 26 patients with 
primary oesophageal cancer the mean length of involved 
oesophageal segment was 5.87 cm (range, 4–8 cm). Type 
II fistula was detected in 10 (21.73%) patients, and type III 
in 16 (34.78%) patients (Table 1). Mean degree of airway 
stenosis was 42.6% (range, 40–85%). 
Oesophageal stenting with the use of partially-covered 
SEMS was performed in all patients. For the bronchial 
tree, the silicone Y-stents were implanted in 20 (43.47%) 
patients, covered tracheal SEMS were used in 10 (21.73%). 
In 6 (13.04%) patients PEG was additionally placed.
Following the DS, appropriate patency of bronchial tree 
was restored and complete fistula coverage was obtained 
in all patients. Oral feeding was restored in all patients and 
Figure 1 Multiplanar reconstructions of CT scans after esophageal and airway stenting. (A) Multiplanar reconstructions of (a, arrow) 
silicone Y-prosthesis and (b, arrow) esophageal prosthesis; (B) one-sided stenting (three implanted stents into one stent).
Figure 2 Bronchoscopic view of fistula in the left main bronchus 
fully covered after oesophageal stenting.
A B
a
b
b
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significant improvement of dysphagia was noted (2.72 vs. 
1.2, P=0.0001). Similarly, dyspnoea improved significantly 
(2.89 vs. 0.34, P=0.0001) as well as performance score (53.2 
vs. 66.3, P=0.0001) (Table 2). Mean survival in the DS group 
was 65.3 days (range, 3–187 days) (Figure 1). Details of the 
results of DS are shown in Table 2. 
The US group included 20 patients with oesophageal 
cancer. Mean body weight loss in this group was 8.54 kg 
(range, 0–20 kg), mean length of involved oesophageal 
segment was 5.6 cm (range,  4–12 cm),  and mean 
bronchial tree stenosis was 25% (range, 10–30%), the rate 
significantly lower than in the DS group (P=0.0001). Type 
II fistula with airway compressed diagnosed in 11 (23.91%) 
patients, type III—in 9 (19.56%) patients. All procedures in 
this group were performed electively using partially covered 
SEMS.
After the stenting procedure, the patency of the 
oesophagus was restored in all the patients, they resumed 
oral diet and dysphagia score improved significantly: 2.65 vs. 
1.0, (P=0.0001). Following stenting, body weight improved 
significantly: −8.54 vs. +0.9, P=0.0089. In 3 patients (11.5%) 
additionally PEG was performed without perioperative 
complications. Mean survival in the US group was 68.9 days 
(range, 30–200 days) (Figure 1). Details of the results of US 
are shown in Table 3.
In the whole cohort of 46 patients the mean follow-up 
was 73.8 days (range, 3–329 days).
Comparison of DS and US has shown the following 
results:
There were no significant differences between the DS 
group and the US group regarding:
 Mean dysphagia score before (2.72 and 2.65, 
respectively) and after stenting (1.2 and 1.0, 
respectively) (P=0.74);
 Mean body weight loss before (11.22 and 8.54, 
respectively) and after stenting (+1.83 and +0.9, 
respectively) (P=0.85);
 BMI before (18.6 and 19.84, respectively) and after 
stenting (19.98 and 20.17) (P=0.54);
 Karnofsky score before (53.2 and 54.3, respectively) 
and after stenting (66.3 and 62.38, respectively) 
(P=0.79); 
Table 1 Clinical and demographic data of the patients
Variable All patients Patients with unilateral stenting Patients with double stenting 
Number of patients 46 20 26
Age: mean (range) 60.8 [31–82] 63.8 [53–82] 58.7 [31–82]
Males/females 37/7 16/4 22/4
Oesophageal cancer 46 20 26
Length of the involvement of the oesophagus (mean)
Oesophageal cancer 5.6 cm (4–12 cm) 5.87 (4–8 cm) 6.57 (4–12 cm)
Bronchial cancer 3.6 (3–4 cm) 3.6 (3–4 cm) 3.6 (3–4 cm)
Location of airway stenosis
Trachea/main carina 20 9 8
LMB 24 11 16
RMB 2 0 2
Fistula type   
II 25 11 10
III 21 9 16
Adjuvant therapy
ChT or CRT, n 24 4/6 4/10
LMB, left main bronchus; RMB, right main bronchus; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer, ChT,  
chemotherapy; CRT, chemoradiotherapy.
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 Overall survival time ( 65.3 vs. 68.9 respectively) 
(P=0.64) (Figure 3);
 Survival time according to the fistula type (range, 
3–187 and 30–200 days respectively) (P=0.79).
There was a significant difference between the DS group 
and the US group regarding severity of airway stenosis 
(42.6% vs. 25% respectively) (P=0.0001). 
 Mean dyspnoea score before (2.83 vs .  1 .7 
respectively) (P=0.0003) and after stenting (0.34 
and 0.09, respectively) (P=0.0028).
Complications
Minor adverse effects occurred in 41 (89.1%) patients. 
Immediately after the procedure, 21 (45.6%) patients 
experienced pain or discomfort in the chest, lasting for 
1–4 days and requiring analgesics, including 14 (30.43%) 
patients in DS group versus 7 (15.21%) in the US group. 
In four (8.7%) patients, including 3 (6.52%) in DS and 1 
(2.17%) in US group, complete expansion of oesophageal 
stent was delayed to 48 hours; no intervention was needed in 
those patients. Four (8.7%) patients in DS group experienced 
transient dysphagia with chest discomfort and bronchoscopy 
was required in 12 (26%) patients, including 10 (21.7%) in 
DS and 2 (4.2%) in US group, due to bronchial secretions 
retention. The risk of complications was significantly higher 
in the DS group (P=0.029, OR =5.63).
Severe complications occurred in 11 patients (23.91%). 
In 1 patient (3.8%) in the DS group massive fatal 
haemorrhage occurred on the third postoperative day. 
In another patient in this group during the restoration 
Figure 3 Kaplan-Meier curve of survival of patients with double 
(DS) and one-sided stenting (US).
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Table 2 Results of patients with double stenting
Variable Before stenting After stenting P value
Mean degree of dyspnoea (range) 2.89 (0 to 3) 0.34 (0 to 1) 0.0001
Mean degree of dysphagia (range) 2.72 (0 to 3) 1.2 (0 to 3) 0.0001
Mean weight gain/loss (kg) −11.22 (3 to 30) 1.83 (−2 to 5) 0.0087
Mean BMI (range) 18.6 (16.41–28.68) 19.98 (16.71 to 28.68) 0.025
Mean Karnofsky score 53.2 (50 to 70) 66.3 (50 to 70) 0.0001
BMI, body mass index.
Table 3 Results of patients with one-sided stenting
Variable Before stenting After stenting P value
Mean degree of dyspnoea (range) 1.71 (1 to 3) 0.09 (0 to 1) 0.0001
Mean degree of dysphagia (range) 2.65 (0 to 3) 1.0 (0 to 2) 0.0001
Mean weight gain/loss (kg) −8.54 (0 to 20) 0.9 (−5 to 4) 0.0089
Mean BMI (range) 19.14 (15.7 to 28.6) 20.17 (16.1 to 28.68) 0.026
Mean Karnofsky score 54.3 (40 to 70) 62.38 (50 to 70) 0.0001
BMI, body mass index.
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of patency of bronchial tree before stenting massive 
haemorrhage occurred. The silicone Y-stent was successfully 
inserted. The patient required mechanical ventilation for 10 
hours, but recovered and was discharged. 
Recurrence of the fistula occurred in 9 (19.56%) 
patients: 6 (13%) in the DS group and in 3 (6.5%) in the 
US group (P=0.13). In all of them the re-opening of fistula 
was associated with stent migration. In 3 out of 6 patients 
after DS partial migration of SEMS was observed, in 2—
complete migration of SEMS was noted and in 1 patient 
migration of a Y-stent occurred. In 2 out of 3 patients after 
US partial migration of SEMS was observed, and in 1—
complete migration of SEMS was noted. 
Re-interventions
In the DS group, 6 (13%) patients required re-intervention 
due to the progression of the tumour or because of stenting-
related complications. In the US group, re-intervention 
was needed in 3 (6.5%) patients because of a recurrence of 
the fistula or stent migration. There was not a significant 
difference between the DS group and the US group 
regarding to re-interventions (P=0.09).
Details of the re-interventions are summarized in Table 4.
After the stenting procedure, 14 (55%) patients in the 
DS group and 10 (50%) patients in the US group received 
adjuvant chemotherapy and/or radiation therapy but no 
effects on survival were detected (P=0.31).
Discussion
Oesophago-airway fistula is one of the most severe 
complications of unresectable oesophageal cancer, but also 
tumours with secondary infiltration of the oesophagus, i.e., 
lung cancer and, rarely, mediastinal tumours. Reportedly, 
fistula occurs in 15% of patients with oesophageal cancer 
and in 1% of patients with lung cancer. The most frequent 
location of fistula is trachea (52–57%), followed by 
Table 4 Re-interventions
Sex and 
age of the 
patient
Fistula 
type
Stenting Complication 
Time from the stenting 
procedure to the  
occurrence of  
complication (days)
Applied treatment
Complication 
after the  
re-intervention
Survival after the 
re-intervention 
(days)
M, 49 I DS Stent migration,  
fistula to the trachea
53 Re-stenting of the  
oesophagus
No 75
M, 58 II DS Reopening of the fistula, 
Y-stent migration
35 Re-stenting of the  
oesophagus
No 40
M, 55 III DS Reopening of the fistula, 
stent migration
28 Re-stenting of the airway No 5
M, 81 III DS Reopening of the fistula, 
stent migration
20 and 14 Re-stenting of the airway Pneumothorax 28
M, 47 I DS Reopening of the fistula, 
stent migration
10 Re-stenting of the  
oesophagus
No 38
M, 61 II DS Reopening of the fistula, 
stent migration
58 Re-stenting of the  
oesophagus, re-stenting of 
the airway (Y-stent), PEG
No 51
M, 56 II US Reopening of the fistula, 
stent migration
54 Re-stenting of the  
oesophagus
No 45
M, 68 II US Reopening of the fistula, 
stent migration
61 Re-stenting of the  
oesophagus
No 37
M, 72 III US Reopening of the fistula, 
stent migration
49 Re-stenting of the  
oesophagus
No 41
US, unilateral stenting; DS, double stenting.
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bronchi (37–40%) and lung parenchyma (3–11%) (9-11). 
Risk factors for the OAF formation include locally 
advanced tumour, the application of radiation therapy and 
chemotherapy, and stenting procedures during the course of 
malignant dysphagia.
Patients with OAF are generally characterized by poor 
general condition, malnutrition, increasing dyspnoea, 
recurrent aspiration pneumonia and progressive cachexia. 
The aim of the palliative treatment in these patients 
is restoration of patency of the oesophagus and airway 
and sealing of the fistula preventing the aspiration of 
oesophageal content to the bronchial tree. Although the 
NCCN guidelines are relatively vague on the topic and 
proposed double stenting for malignant OAFs, than the 
ESGE clearly recommends esophageal self-expanding 
metallic stent insertion as the first line, with double stenting 
mentioned as worth considering if the esophageal SEMS 
does not seal the fistula (12,13).
Successful management of OAF requires complete 
fistula coverage by the oesophageal stent and, in case of 
airway stenosis, double stenting of the airway and the 
oesophagus. According to the literature, the effectiveness 
of such management is between 75% and 100% (14-21). 
Our results, showing a technical success rate of 98%, are 
consistent with the published data.
Par t i a l l y  covered  or  fu l l y  covered  SEMS are 
recommended in case of OAF. It should be noted, that in 
case of partial obstruction or compression of the airway, 
SEMS expansion may exacerbate its compression to the 
degree of impeding suffocation. As restoration of airway 
patency may be technically difficult in such situation, 
tracheobronchial Y-stent should be inserted prior to 
the oesophageal stenting. The use of silicone Y-stents is 
recommended by most authors (6,7,12,22).
Oesophageal SEMS are characterized by simple 
implantation as well as a relatively low migration and 
obstruction rate. Implantation of the silicone Y-stents is 
technically more difficult, but these stents have very low 
migration rate and are well tolerated by patients, even 
in a long-term follow-up (6,22). Proper stent expansion 
is crucial in patients with OAF. Wang et al. describe the 
‘funnel phenomenon’ in case of incomplete expansion of 
the proximal end of the SEMS, resulting in the formation 
of an empty space between the stent and the oesophageal 
wall, making the stenting procedure ineffective. Attempts to 
dilate the stent, or additional stenting procedure are usually 
ineffective (23).
The most common complications after the stenting 
procedure include stent migration and obstruction. Stent 
migration occurs in 4–15% of patients (20-27). In our group 
this occurred in 9 (19.5%) patients, which is consistent with 
the literature data. Ke et al. consider double stenting as 
associated with high rate of oesophageal stent migration (27).
Freitag et al. compared the effectiveness of double 
stenting (oesophageal and airway) and unilateral stenting 
(airway only) and concluded that survival was significantly 
longer in patients in the double stenting group—110 vs. 
24 days (14). In should be stressed, however, that similarly 
to our study, the clinical characteristics of patients in 
DS and US group differed, and this selection bias makes 
any comparison disputable. Shin et al. demonstrated that 
among 61 patients who underwent unilateral stenting the 
fistula was not completely covered in 12 patients and fistula 
recurrence occurred in 17 patients (26). 
Recurrence rate of the OAF is reported in a wide range 
(0–35%) and its risk factors are not well known. They 
can be associated with disease progression, but also with 
pressure necrosis and erosion on the oesophageal and 
airway wall after double stenting due to significant and 
competing radial force (24-26). For this reason, DS should 
be avoided if is possible. For recurrent OAF, double stenting 
may be more effective that unilateral stenting. Rodriguez 
et al. also confirm the advantage of double stenting over 
unilateral stenting (16). In the present study, partially 
covered SEMS were used in all patients and the survivals 
were not statistically significantly different depending on 
the way of treatment (DS or US). Improvement of the 
performance score after stenting was also similar in both 
groups. It should be noted that the rate of re-interventions 
was 19.56%, and was associated with disease progression, 
fistula recurrence and stent migration. 
In our group, all re-interventions were successfully 
performed and the improvement of patients’ quality of life 
was achieved. It suggests the need of active management of 
these patients, despite the obvious palliative setting. The 
most difficult problem is inevitable disease progression and 
poor general condition of patients, which can hinder the 
effective re-intervention. The re-interventions rate was not 
significantly different between both groups, and the patients 
with DS had greater progression and recurrence rate of 
the fistula, higher rate of complications and higher rate of 
re-interventions. Our results suggest that US is a safe and 
effective treatment in patients in whom the airway stenosis 
does not exceed 30% of the lumen.
Depending on patient’s clinical status, body weight 
and BMI loss, and the feasibility of maintaining adequate 
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oral feeding, PEG should be considered. In our group, a 
statistically significant increase in body weight was observed 
after stenting, but there was no significant difference 
between the DS and the US group.
Literature data regarding benefit from adjuvant 
chemotherapy and/or radiation therapy are conflicting. 
Some authors report a positive effect on closure of OAF 
and survival (28,29). Hamai et al. and Herth et al. reported 
longer survival in patients who underwent adjuvant therapy 
(30,31). In our study adjuvant therapy after stenting did not 
influence survival ratio among the patients from groups DS 
and US, but the number of patients in these subgroups were 
too small to allow for definitive conclusion in this regard. 
In the published literature, there is lack of data on 
the comparison of DS and US and the results of these 
procedures in patients with malignant oesophageal fistula, 
which is obvious given the different patients’ populations. 
Our results demonstrate the effectiveness of US in patients 
with minor airway stenosis, with low rate of complications. 
Double stenting may be an alternative to US in patients 
with bronchial tree stenosis exceeding 30%. While 
considering double stenting procedure, a higher rate of 
long-term re-interventions should be taken into account.
The limitations of the study include its retrospective 
nature and relatively small number of patients, which is due 
to the single-centre data collection. However, most analyses 
of rare clinical problems, like OAF, tend to include small 
series of patients. 
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